title: Acute adverse cutaneous reaction after the concomitant use of venlafaxine and orphenadrine citrate plus paracetamol in a depressed patient.
authors.forename: G N
authors.initials: GN
authors.lastname: Papadimitriou
authors.forename: C G
authors.initials: CG
authors.lastname: Theleritis
authors.forename: C C
authors.initials: CC
authors.lastname: Papageorgiou
authors.forename: D
authors.initials: D
authors.lastname: Kalogeromitros
authors.forename: E
authors.initials: E
authors.lastname: Syrigou
authors.forename: S
authors.initials: S
authors.lastname: Gregoriou
authors.forename: A D
authors.initials: AD
authors.lastname: Rabavilas
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000009:adverse effects*; D003866:Depressive Disorder / Q000188:drug therapy*; D004338:Drug Combinations; D003875:Drug Eruptions / Q000209:etiology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects*; D009966:Orphenadrine / Q000008:administration & dosage / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D004338:Drug Combinations; D009125:Muscle Relaxants, Central; D009966:Orphenadrine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride